These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 28260367)

  • 1. [The pharmacogenomics of CFH Y402H and wet age-related macular degeneration].
    Chen LL; Chen YY
    Zhonghua Yan Ke Za Zhi; 2017 Feb; 53(2):144-147. PubMed ID: 28260367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics of Complement Factor H Y402H Polymorphism and Treatment of Neovascular AMD with Anti-VEGF Agents: A Meta-Analysis.
    Chen G; Tzekov R; Li W; Jiang F; Mao S; Tong Y
    Sci Rep; 2015 Sep; 5():14517. PubMed ID: 26411831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of complement factor H Y402H polymorphism on the outcome of photodynamic therapy in age-related macular degeneration.
    Seitsonen SP; Jarvela IE; Meri S; Tommila PV; Ranta PH; Immonen IJ
    Eur J Ophthalmol; 2007; 17(6):943-9. PubMed ID: 18050121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement factor H Y402H gene polymorphism and response to intravitreal bevacizumab in exudative age-related macular degeneration.
    Nischler C; Oberkofler H; Ortner C; Paikl D; Riha W; Lang N; Patsch W; Egger SF
    Acta Ophthalmol; 2011 Jun; 89(4):e344-9. PubMed ID: 21232084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of the CFH Y402H Polymorphism with the 1-Year Response of Exudative AMD to Intravitreal Anti-VEGF Treatment in the Brazilian Population.
    Medina FMC; Motta AALD; Takahashi WY; Carricondo PC; Motta MMDS; Melo MB; Vasconcellos JPC
    Ophthalmic Res; 2019; 61(3):168-173. PubMed ID: 28641277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An analysis of the CFH Y402H genotype in AMD patients and controls from the UK, and response to PDT treatment.
    Goverdhan SV; Hannan S; Newsom RB; Luff AJ; Griffiths H; Lotery AJ
    Eye (Lond); 2008 Jun; 22(6):849-54. PubMed ID: 17464302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement factor H Y402H and C-reactive protein polymorphism and photodynamic therapy response in age-related macular degeneration.
    Feng X; Xiao J; Longville B; Tan AX; Wu XN; Cooper MN; McAllister IL; Isaacs T; Palmer LJ; Constable IJ
    Ophthalmology; 2009 Oct; 116(10):1908-12.e1. PubMed ID: 19692124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of CC-cytokine ligand 2 and complementary factor H Y402H polymorphisms and their interactional association with age-related macular degeneration.
    Bonyadi M; Foruzandeh Z; Mohammadian T; Fotouhi N; Soheilian M; Jabbarpoor Bonyadi MH; Javadzadeh A; Moein H; Yaseri M
    Acta Ophthalmol; 2016 Dec; 94(8):e779-e785. PubMed ID: 27316788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of the polymorphism Y402H in the CFH gene with response to anti-VEGF treatment in age-related macular degeneration: a systematic review and meta-analysis.
    Hong N; Shen Y; Yu CY; Wang SQ; Tong JP
    Acta Ophthalmol; 2016 Jun; 94(4):334-45. PubMed ID: 27151934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of ARMS2/LOC387715 A69S and CFH Y402H risk effect in wet-type age-related macular degeneration: a meta-analysis.
    Jabbarpoor Bonyadi MH; Yaseri M; Nikkhah H; Bonyadi M; Nazari R; Soheilian M
    Int Ophthalmol; 2019 Apr; 39(4):949-956. PubMed ID: 29423786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Association between Y402H, E318D and R102G polymorphisms of complement proteins genes and the response to intravitreal anti-VEGF treatment in patients with neovascular age-related macular degeneration].
    Kubicka-Trząska A; Karska-Basta I; Kobylarz J; Dziedzina S; Sanak M; Romanowska-Dixon B
    Klin Oczna; 2016; 118(2):114-21. PubMed ID: 29912491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of genetic base in the treatment of age-related macular degeneration.
    Gourgouli K; Gourgouli I; Tsaousis G; Spai S; Niskopoulou M; Efthimiopoulos S; Lamnissou K
    Int Ophthalmol; 2020 Apr; 40(4):985-997. PubMed ID: 31916060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of the Complement Factor H Y402H Polymorphism and Response to Anti-Vascular Endothelial Growth Factor Treatment in Age-Related Macular Degeneration: An Updated Meta-Analysis.
    Roshanshad A; Moosavi SA; Arevalo JF
    Ophthalmic Res; 2024; 67(1):358-386. PubMed ID: 38754401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human complement factor H Y402H polymorphism causes an age-related macular degeneration phenotype and lipoprotein dysregulation in mice.
    Landowski M; Kelly U; Klingeborn M; Groelle M; Ding JD; Grigsby D; Bowes Rickman C
    Proc Natl Acad Sci U S A; 2019 Feb; 116(9):3703-3711. PubMed ID: 30808757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the association between CFH Y402H polymorphism and response to intravitreal ranibizumab in patients with neovascular age-related macular degeneration (nAMD).
    Mohamad NA; Ramachandran V; Ismail P; Mohd Isa H; Chan YM; Ngah NF; Md Bakri N; Ching SM; Hoo FK; Wan Sulaiman WA; Inche Mat LN; Hazmi Mohamed M
    Bosn J Basic Med Sci; 2018 Aug; 18(3):260-267. PubMed ID: 29579408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age-related macular degeneration and modification of systemic complement factor H production through liver transplantation.
    Khandhadia S; Hakobyan S; Heng LZ; Gibson J; Adams DH; Alexander GJ; Gibson JM; Martin KR; Menon G; Nash K; Sivaprasad S; Ennis S; Cree AJ; Morgan BP; Lotery AJ
    Ophthalmology; 2013 Aug; 120(8):1612-8. PubMed ID: 23562165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CFH Y402H and VEGF Polymorphisms and Anti-VEGF Treatment Response in Exudative Age-Related Macular Degeneration.
    Kepez Yildiz B; Ozdek S; Ergun MA; Ergun S; Yaylacioglu Tuncay F; Elbeg S
    Ophthalmic Res; 2016; 56(3):132-8. PubMed ID: 27404493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement factor H polymorphism, complement activators, and risk of age-related macular degeneration.
    Despriet DD; Klaver CC; Witteman JC; Bergen AA; Kardys I; de Maat MP; Boekhoorn SS; Vingerling JR; Hofman A; Oostra BA; Uitterlinden AG; Stijnen T; van Duijn CM; de Jong PT
    JAMA; 2006 Jul; 296(3):301-9. PubMed ID: 16849663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to photodynamic therapy.
    Brantley MA; Edelstein SL; King JM; Plotzke MR; Apte RS; Kymes SM; Shiels A
    Eye (Lond); 2009 Mar; 23(3):626-31. PubMed ID: 18292785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of complement factor H Y402H gene polymorphism with different subtypes of exudative age-related macular degeneration.
    Wegscheider BJ; Weger M; Renner W; Steinbrugger I; März W; Mossböck G; Temmel W; El-Shabrawi Y; Schmut O; Jahrbacher R; Haas A
    Ophthalmology; 2007 Apr; 114(4):738-42. PubMed ID: 17398321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.